Paloma Pharmaceuticals, Inc.
1 clinical trials · Sponsor
◉ Watch Paloma Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (NCT01033721) | Paloma Pharmaceuticals, Inc. | 2010-06-01 |
Track Paloma Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.